Edwards Lifesciences
1,158 hedge funds and large institutions have $47.9B invested in Edwards Lifesciences in 2020 Q4 according to their latest regulatory filings, with 165 funds opening new positions, 409 increasing their positions, 391 reducing their positions, and 78 closing their positions.
112% more first-time investments, than exits
New positions opened: 165 | Existing positions closed: 78
85% more call options, than puts
Call options by funds: $235M | Put options by funds: $127M
16% more capital invested
Capital invested by funds: $41.1B → $47.9B (+$6.74B)
7% more funds holding
Funds holding: 1,083 → 1,158 (+75)
5% more repeat investments, than reductions
Existing positions increased: 409 | Existing positions reduced: 391
0.2% less ownership
Funds ownership: 82.91% → 82.71% (-0.2%)
16% less funds holding in top 10
Funds holding in top 10: 19 → 16 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
+$199M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$196M |
| 3 |
Bank of New York Mellon
New York
|
+$98M |
| 4 |
SFFS
Stonehage Fleming Financial Services
St. Helier,
Jersey
|
+$78.1M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$74.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$175M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$161M |
| 3 |
Goldman Sachs
New York
|
-$147M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$101M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$100M |
EW Hedge Fund Activity: Q4 2020 in Review
1,158 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2020, worth a combined $47.9B — up 16% from $41.1B a quarter earlier.
Buyers outnumbered sellers: 165 funds opened new EW positions and 78 closed out — a net gain of 87 holders — while 409 added to existing stakes and 391 trimmed.
The largest buyer was Harding Loevner, adding an estimated $199M. The largest seller was Fidelity Investments, cutting an estimated $175M.
- 1,158 institutional investors held Edwards Lifesciences (EW) as of Q4 2020, up from 1,083 in Q3 2020.
- Funds reported $47.9B of Edwards Lifesciences stock for Q4 2020, up 16% quarter-over-quarter.
- 165 funds opened new Edwards Lifesciences positions in Q4 2020 and 78 closed out, a net change of +87 holders.
- The largest Edwards Lifesciences buyer in Q4 2020 was Harding Loevner, an estimated $199M added.
- The largest Edwards Lifesciences seller in Q4 2020 was Fidelity Investments, an estimated $175M sold.
Based on aggregated 13F filings for Q4 2020.